1. Home
  2. JMIA vs ANL Comparison

JMIA vs ANL Comparison

Compare JMIA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jumia Technologies AG each representing two

JMIA

Jumia Technologies AG each representing two

HOLD

Current Price

$7.01

Market Cap

899.2M

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$11.85

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
JMIA
ANL
Founded
2012
2004
Country
Germany
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
899.2M
731.6M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
JMIA
ANL
Price
$7.01
$11.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$16.75
$20.00
AVG Volume (30 Days)
2.8M
151.7K
Earning Date
05-07-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$22.18
$36.02
Revenue Next Year
$23.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.02
$0.88
52 Week High
$14.72
$17.25

Technical Indicators

Market Signals
Indicator
JMIA
ANL
Relative Strength Index (RSI) 45.82 46.75
Support Level $6.51 $6.92
Resistance Level $9.49 $12.09
Average True Range (ATR) 0.37 1.33
MACD -0.01 -0.13
Stochastic Oscillator 25.14 27.74

Price Performance

Historical Comparison
JMIA
ANL

About JMIA Jumia Technologies AG each representing two

Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: